MONDAY, March 11, 2019 — A moderate level of muscular
Read moreModerate Muscle Strength Linked to Lower Risk for T2DM
Home »
Bristol-Myers Squibb’s Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial
PRINCETON, N.J.–(BUSINESS WIRE)– September 12, 2018 — Bristol-Myers Squibb Company
Read moreEisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018
TOKYO and CAMBRIDGE, Mass., July 25, 2018 (GLOBE NEWSWIRE) —
Read more